Gene Therapy for Rare Diseases: Latest Updates

Video

Kinnari Patel, PharmD, president and chief operating officer of Rocket Pharmaceuticals, discussed Rocket Pharma’s programs.

“We're really excited that rocket is focused on rare diseases, whether it's a bone marrow derived disease, or it's a heart derived disease, we're able to work with patient communities, collaborators, and scientists around Europe and US to bring these amazing, innovative therapies to patients."

While international Rare Disease Day has come and gone, groundbreaking work in diseases such as Danon disease, leukocyte adhesion deficiency type 1 (LAD-1), pyruvate kinase deficiency (PKD), and Fanconi anemia continue to push forward.

Rocket Pharma is developing gene therapies to help meet the unmet needs in these diseases. The company has programs in phase 1 trials for Danon disease (NCT03882437) and PKD (NCT04105166), a phase 1/2 program in LAD-1 (NCT03812263), and a phase 2 program in Fanconi anemia subtype A (NCT04069533). Rocket reported positive data in Danon disease, LAD-1, and Fanconi anemia in 2022.

CGTLive spoke with Kinnari Patel, PharmD, president and chief operating officer, Rocket Pharma, to learn more about the company’s programs in these rare diseases as well as upcoming pipeline milestones.

REFERENCE
Rocket Pharmaceuticals reports fourth quarter and full year 2021 financial and operational results. News release. Rocket Pharmaceuticals. February 24, 2022. https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2021

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.